${h}_{R}$ | Rate of Treg cell inhibition by Sunitinib | 0.227 | day | [45] |

${K}_{R}$ | Rate of Treg cell depletion from chemotherapy toxicity | $5.7\times {10}^{-1}$ | day | [45] |

${\alpha}_{1}$ | Determines the scope of influence of KRAS-mutant tumor cells T | $1\times {10}^{7}$ | unitless | [25] |

${\lambda}_{R}$ | Efficacy of Sunitinib in inhibiting the immunosuppressive activity of Tregs | 50.02 | L mg | [45] |

${\delta}_{R}$ | Chemotherapy toxicity on Tregs | $2\times {10}^{-1}$ | L mg | [32] |

${\eta}_{S}$ | Rate of excretion and elimination of Sunitinib | 0.277 | day | [45] |

${a}_{m}$ | Growth rate of mutant tumor cells (colorectal cancer) | $2.31\times {10}^{-1}$ | day | [32] |

$\mu $ | Maximum mutation rate of wild-type tumor cells | $4\times {10}^{-5}$ | day | [55] |

${K}_{M}$ | Concentration of Irinotecan chemotherapy that leads to a half-maximal rate of mutation of wild-type tumor cells T | $1\times {10}^{3}$ | mg L | Est. |

${\delta}_{TR}$ | Efficacy of the second type of chemotherapy drug of killing irinotecan-resistant tumor cells | $2\times {10}^{-1}$ | L mg | [32] |

${\gamma}_{2}$ | Rate of excretion and elimination of the hypothetical chemotherapy drug | $4.077\times {10}^{-1}$ | day | [32] |

${\eta}_{F}$ | Degradation rate of anti-TGF-beta (Fresolimumab) | 0.033 | day | Est. from [56] |

${b}_{2}$ | Rate of loss of free TGF-β due to binding with anti-TGF-β | 100 | L mg | Est. from [56] |

${b}_{3}$ | Rate of loss of free anti-TGF-β due to binding with TGF-β | $2.5\times {10}^{-13}$ | L IU | Est. from [56] |

${\lambda}_{M0}$ | Differentiation rate of M0 macrophages into an M1 or M2 macrophage | $1\times {10}^{-4}$ | day | Est. from [31] |